Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

The case focuses on allegations that Skye overstated nimacimab’s prospects following a Phase 2a failure disclosure.

Overview

Multiple investor law firms are urging SKYE shareholders to move by January 16, 2026 to seek lead-plaintiff appointment.
The litigation remains at the pre-certification stage under Sections 10(b) and 20(a) and SEC Rule 10b-5.
The putative class covers purchases from November 4, 2024 through October 3, 2025 and alleges misstatements about nimacimab’s efficacy and prospects.
On October 6, 2025 Skye reported Phase 2a topline results showing the nimacimab monotherapy arm missed the primary weight-loss endpoint and showed lower-than-expected drug exposure.
SKYE shares fell about $2.85, roughly 60%, to close at $1.90 on the disclosure date.